20 March 2025
: Case report 
IL-17 Inhibitor Secukinumab Achieves Remission in Relapsing Polychondritis: A Case Report
Diagnostic / therapeutic accidents
Stefka Neycheva
BDEF 1*, Adriana Kamburova BCE 1
DOI: 10.12659/AJCR.946916
Am J Case Rep 2025; 26:e946916
Table 1. Laboratory tests. Blood parameters at the onset of the relapsing polychondritis and their changes during treatment with bDMARDs. Notably, there was an improvement in acute-phase reactants such as ESR and CRP, as well as normalization of leukocyte and thrombocyte counts, reflecting the suppression of disease activity.
| Jan 2023 | Feb 2023 | July 2023 | April 2024 | Oct 2024 | Reference ranges | |
|---|---|---|---|---|---|---|
| WBC | 20.35 | 20.5 | 19.22 | 10.85 | 5.97 | 3.5–10.5×10/L |
| RBC | 4.62 | 3.84 | 4.52 | 4.47 | 4.75 | 4.2–5.4×10/L |
| HGB | 100 | 82 | 105 | 123 | 120 | 120–160 g/L |
| MCV | 71.6 | 70.1 | 74.8 | 74.7 | 73.4 | 82–92 fL |
| HCT | 0.33 | 0.27 | 0.34 | 0.33 | 0.31 | 0.36–0.46% |
| PLT | 434 | 305 | 610 | 407 | 430 | 140–440×10/L |
| ESR | 88 | 97 | 94 | 22 | 20 | 0–15 mm/h |
| CRP | 190.3 | 159 | 106.34 | 7.1 | 5.35 | 0–5 mg/L |
| Total protein | 74.6 | 62.7 | 78.1 | – | – | 63–85 g/L |
| Albumin | 24.8 | 29.4 | 41.5 | – | – | 35.0–52.0 g/L |
| ASAT | 22.3 | 9.9 | 16.5 | 13.6 | 40.7 | 5–40 U/L |
| ALAT | 38.6 | 13.7 | 22.5 | 9.4 | 37.9 | 5–40 U/L |
| Creatinine | 65 | 57 | 64 | 60 | 61 | 58.0–100.0 μmol/L |
| Urea | 3.8 | 4.4 | 3.1 | 3.6 | 4 | 2.8–8.3 mmol/L |
| bDMARDs – biologic disease-modifying antirheumatic drugs; WBC – white blood cells; RBC – red blood cells; HGB – hemoglobin; MCV – mean cell volume; HCT – hematocrit; PLT – platelets; ESR – erythrocyte sedimentation rate, ASAT – aspartate aminotransferase; ALAT – alanine aminotransferase; CRP-C – reactive protein. | ||||||